Palliative Assessment
Use when asked to administer, score, or explain a Palliative Assessment — symptom-focused evaluation using the Edmonton Symptom Assessment System-revised (ESAS-r) — grounded in FormExamples/form-examples.
Symptom-focused palliative care assessment using the Edmonton Symptom Assessment System-revised (ESAS-r) alongside performance status, goals-of-care documentation, medication and symptom-control planning, and psychosocial and spiritual review, to guide individualized palliative management.
Scoring
Instrument: ESAS-r — 10 symptoms each rated 0–10, total 0–100.
- None (0–10) — minimal symptom burden.
- Mild (11–30) — low burden; routine review.
- Moderate (31–60) — meaningful burden; escalate symptom control.
- Severe (61–100) — high burden; urgent review/hospice referral.
- Individual flag: any single symptom ≥ 7 triggers urgent single-symptom review regardless of the total.
What it covers
Demographics; primary diagnosis and prognosis; ESAS-r symptom scoring; performance status (PPS/KPS/ECOG); goals of care and advance care planning documents; medications and symptom-control plan; psychosocial and spiritual concerns; carer and family support; and a multidisciplinary plan with referrals.
Common pitfalls
- Averaging away a single severe symptom in the total score — the individual-symptom flag (≥ 7 on any item) exists precisely because a moderate total can hide one severely distressing symptom that needs urgent attention on its own.
- Treating goals-of-care documentation as a one-time conversation — goals of care evolve as disease progresses; the documentation should be revisited, not fixed at the first assessment.
- Skipping spiritual and psychosocial review because the focus is physical symptoms — these domains materially affect a patient's experience and are core, not supplementary, to palliative assessment.
Learn more
- FormExamples: palliative-assessment for the full implementation, clinical references, and worked examples.
- Oncology Assessment for a related assessment relevant to advanced cancer.